Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Benefit-Cost Analysis | Global Governance | Chronic Disease/Risk | Mental Health | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
Resource PackPublication, Teaching Resource 2017Resource Pack: Disease Control Priorities
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced …
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced by the Disease Control Priorities 3 (DCP3) to inform program design and resource allocation at the global and country levels. Analyses focus on the effectiveness, cost, and cost-effectiveness of priority interventions. Learn more by visiting the DCP3 website.
Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Infectious Diseases | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Child/Nutrition | Injuries/Accidents | Health Systems | Economics/Finance | Health/Medicine | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2021Impact of COVID-19 on Cancer Diagnosis and Survival in Chile
This paper estimates the impact of the COVID-19 pandemic on delays in cancer diagnosis in …
This paper estimates the impact of the COVID-19 pandemic on delays in cancer diagnosis in Chile, using a microsimulation model of five cancers: breast, cervix, colorectal, prostate, and stomach. The model simulates cancer incidence and progression, as well as stage-specific cancer detection and survival probabilities, and was calibrated to empirical data on monthly detected cases, stage at diagnosis, and 5-year net survival. The analysis accounted for the impact of COVID-19 on month-by-month excess mortality and…
Calibration/Validation | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Microsimulation | Latin America & Caribbean -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Preferences/Values | Costing Methods | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Chronic Disease/Risk | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global | North America -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Preferences/Values | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Oceania -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Calibration/Validation | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Calibration/Validation | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Cost-Effectiveness Analysis | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa